NY-REVBITS
18.3.2024 14:01:28 CET | Business Wire | Press release
RevBits, winner in eight categories of the 2024 Globee Cybersecurity Awards®, continues to advance the state of cybersecurity solutions. The Globee Awards recognizes the world’s top providers by their organizational performance, innovations, products and services, leadership, initiatives, and more.
RevBits is pleased to be the recipient of eight awards in multiple categories.
Company-level awards:
- Silver | Most Innovative Security Company
- Silver | Cybersecurity Chief Technology Officer of the Year
Product-level awards:
- Gold | Security Platform
- Gold | Deception-based Security
- Gold | Endpoint Detection, Visibility & Response
- Silver | Privileged Access Control, Security, & Management
- Bronze | Email Security and Management
- Bronze | Zero Trust Security
“This recognition of eight awards, for our company, CTO and all six of our main product modules is extremely gratifying. It confirms both the breadth and depth of our solution is unrivaled in the crowded cybersecurity market,” said David Schiffer, CEO. “One of our tag lines is ‘Every CISO’s Dream’ and RevBits’ Cybersecurity Intelligent Platform, truly is that.”
“Innovation is at the core of everything we do,” said Mucteba Celik, CTO. “We probably have the broadest footprint of any cybersecurity software vendor in the market. And still every single one of our products has innovative and unique features that make it stand out from other mainstream solutions. We have wider coverage with superior products. We continue to innovate, for instance in 2023 we have enabled three of our solutions to be fully deployable in Air-Gapped environments (EPS&EDR, PAM, and DT solutions). Once again it is gratifying to see this validated by the experts.”
About RevBits
RevBits is a cybersecurity leader that delivers new levels of security IQ, using behavioral analysis, artificial intelligence, and machine learning, through RevBits Cyber Intelligence Platform (CIP). RevBits CIP is an extensible platform that can plug into Syslog, LogRhythm, Splunk, SIEM, and other log management and security platforms. The integrated dashboard, or mobile app, allows a CISO to see the status of all major components within their cyber defense.
RevBits is taking cybersecurity to the next level, innovating new capabilities with multiple patented technologies to ensure our competitive advantage. RevBits eliminates security gaps between siloed products that cannot integrate, correlate, or analyze unrelated alerts, logs, events, or behavior analytics. RevBits patented technology includes best-in-class cybersecurity modules and provides superior protection by seamlessly working together.
RevBits is headquartered in Mineola, NY with offices in Princeton, NJ; Boston, MA; Houston, TX; Antwerp, Belgium; and London, England. For more information on RevBits please visit www.revbits.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318597175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom